Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial
DiscussionThe results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. Therefore, our primary outcome measures are markers of neuroinflammation (IL-6, MCP-1, and IBA-1) and of the gelatinase pathway (MMP2/9 and VEGF) in CSF. Secondly, we will look at the progression of hemorrhagic markers on 7-T MRI before and after treatment and investigate serum biomarkers.Trial registrationClinicalTrials.gov NCT05680389. Registered on January 11, 2023 (Source: Trials)
Source: Trials - June 5, 2023 Category: Research Source Type: clinical trials
Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease
Condition: Mycobacterium Avium Complex Pulmonary Disease Intervention: Drug: Minocycline Sponsor: Radboud University Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 16, 2023 Category: Research Source Type: clinical trials
